NZ502869A - Solid pharmaceutical dosage forms of glitazone in a particulate dispersion - Google Patents

Solid pharmaceutical dosage forms of glitazone in a particulate dispersion

Info

Publication number
NZ502869A
NZ502869A NZ502869A NZ50286998A NZ502869A NZ 502869 A NZ502869 A NZ 502869A NZ 502869 A NZ502869 A NZ 502869A NZ 50286998 A NZ50286998 A NZ 50286998A NZ 502869 A NZ502869 A NZ 502869A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical dosage
glitazone
dosage forms
solid pharmaceutical
particulate dispersion
Prior art date
Application number
NZ502869A
Other languages
English (en)
Inventor
Isaac Ghebre-Sellassie
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ502869A publication Critical patent/NZ502869A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
NZ502869A 1997-08-21 1998-07-29 Solid pharmaceutical dosage forms of glitazone in a particulate dispersion NZ502869A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5619597P 1997-08-21 1997-08-21
PCT/US1998/015693 WO1999008660A1 (en) 1997-08-21 1998-07-29 Solid pharmaceutical dosage forms in form of a particulate dispersion

Publications (1)

Publication Number Publication Date
NZ502869A true NZ502869A (en) 2002-10-25

Family

ID=22002810

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ502869A NZ502869A (en) 1997-08-21 1998-07-29 Solid pharmaceutical dosage forms of glitazone in a particulate dispersion

Country Status (17)

Country Link
US (1) US20010048946A1 (enExample)
EP (1) EP1011640A1 (enExample)
JP (1) JP2001515029A (enExample)
KR (1) KR20010023085A (enExample)
AR (1) AR018252A1 (enExample)
AU (1) AU8600098A (enExample)
BR (1) BR9811972A (enExample)
CA (1) CA2292586C (enExample)
CO (1) CO4960652A1 (enExample)
GT (1) GT199800136A (enExample)
HN (1) HN1998000115A (enExample)
NZ (1) NZ502869A (enExample)
PA (1) PA8458101A1 (enExample)
PE (1) PE109599A1 (enExample)
SV (1) SV1998000104A (enExample)
WO (1) WO1999008660A1 (enExample)
ZA (1) ZA987551B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2108575C (en) * 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
DE69214956T2 (de) * 1991-08-02 1997-04-10 Wilcom Tufting Pty. Ltd., Chippendale, Neusuedwales Verfahren und system zum tuften
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2002024168A1 (fr) * 2000-09-25 2002-03-28 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide medicinale
CA2363902C (en) * 2000-12-07 2005-07-26 Warner-Lambert Company Process and system for controlled-release drug delivery
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
DE60329188D1 (de) 2002-08-12 2009-10-22 Bend Res Inc Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US8273371B2 (en) * 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
BRPI0417360A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US9504658B2 (en) * 2004-11-09 2016-11-29 Board Of Regents, The University Of Texas System Stabilized HME composition with small drug particles
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
ES2401992T3 (es) * 2004-12-30 2013-04-26 Pierre Fabre Medicament Dispersión sólida estable de un derviado de alcaloide de vinca y procedimiento para su preparación
FR2880274B1 (fr) * 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
WO2006122021A1 (en) * 2005-05-10 2006-11-16 Novartis Ag Extrusion process for making compositions with poorly compressible therapeutic compounds
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
CA2673418A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
MX2010014566A (es) * 2008-07-03 2011-02-15 Novartis Ag Proceso de granulacion de fundido.
WO2010136604A1 (en) * 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
CA2824639A1 (en) 2011-02-17 2012-08-23 Ashish Chatterji A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
PH12014500593A1 (en) * 2011-09-14 2019-09-02 Celgene Corp Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
CA2108575C (en) * 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
CA2124821C (en) * 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Novel solid pharmaceutical dispersions
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
US20010048946A1 (en) 2001-12-06
AU8600098A (en) 1999-03-08
WO1999008660A1 (en) 1999-02-25
PA8458101A1 (es) 2001-12-14
CO4960652A1 (es) 2000-09-25
CA2292586C (en) 2006-02-14
ZA987551B (en) 1999-02-23
HN1998000115A (es) 1999-06-02
KR20010023085A (ko) 2001-03-26
GT199800136A (es) 2000-02-11
BR9811972A (pt) 2000-08-15
EP1011640A1 (en) 2000-06-28
AR018252A1 (es) 2001-11-14
JP2001515029A (ja) 2001-09-18
SV1998000104A (es) 1999-07-02
CA2292586A1 (en) 1999-02-25
PE109599A1 (es) 1999-12-19

Similar Documents

Publication Publication Date Title
NZ502869A (en) Solid pharmaceutical dosage forms of glitazone in a particulate dispersion
GB9416600D0 (en) Pharmaceutical formulation
HUP0200248A3 (en) Oxamic acids and derivatives as thyroid receptor ligands, pharmaceutical compositions containing them as active ingredient and their use
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
EP0868910A3 (de) Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen
IL112637A0 (en) A pharmaceutical composition containing oxybutynin and methods for the preparation thereof
EP0864326A3 (de) Mehrphasige wirkstoffhaltige Zubereitungsformen
AU1063799A (en) Taste masked pharmaceutical compositions
EP2258342A3 (en) Improvements in and relating to carrier particles for use in dry powder inhalers
AU2003274680A8 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
SI0868912T1 (en) Use of redispersible polymer powders or polymer granulates for coating pharmaceutical or agrochemical delivery forms
EP1281400A3 (en) Pharmaceutical compositions containing ascomycin derivatives
IL132453A0 (en) Gastroretentive controlled release microspheres for improve drug delivery
AU8781798A (en) Sustained release drug delivery system suitable for oral administration
AU5914999A (en) Controlled release drug delivery
AU2034395A (en) Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance
AU5335698A (en) Pharmaceutical formulations with delayed drug release
DE69931925D1 (de) 2-chinolonen enthaltende arzneimittel
CA2339765A1 (en) Compounds and compositions for delivering active agents
JP2001515029A5 (enExample)
AU4067999A (en) Inorganic material for radioactive drug delivery
CA2354034A1 (en) Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period
DE69710757D1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
DE69934582D1 (de) Delavirdin tablettenformulierung
HUP0104687A3 (en) Methods for preparing coated drug particles and pharmaceutical formulations thereof

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)